data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

BridgeBio Pharma

(NASDAQ:BBIO)

Intraday

$24.95

0[0.00%]

After-Hours

$24.95

0[0.00%]

Perks Buy Compare Brokers

$24.95

0[0.00%]

At close: Apr 18

$24.95

0[0.00%]

After Hours: 4:21PM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for BridgeBio Pharma Stock (NASDAQ:BBIO)

BridgeBio Pharma Stock (NASDAQ: BBIO)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, April 08, 2024

Reported Sunday, BridgeBio Pharma Presented Results From The Exploratory Cardiac Magnetic Resonance Imaging Substudy Of ATTRibute-CM, Its Phase 3 trial Of Acoramidis In ATTR-CM
Benzinga Newsdesk - Apr 8, 2024, 2:50AM

Wednesday, March 20, 2024

JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $45
Benzinga Newsdesk - Mar 20, 2024, 6:28AM

Tuesday, March 19, 2024

Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $70
Benzinga Newsdesk - Mar 19, 2024, 8:35AM

Monday, March 11, 2024

Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $60
Benzinga Newsdesk - Mar 11, 2024, 9:16AM

Wednesday, March 06, 2024

BridgeBio Pharma Prices Public Offering Of 8,620,690 Common Shares At $29/Share
Benzinga Newsdesk - Mar 6, 2024, 2:35AM

Tuesday, March 05, 2024

BridgeBio Pharma shares are trading lower after the company announced a $250 million proposed public offering. Also, Mizuho maintained a Buy rating on the stock but lowered its price target from $60 to $53.
Benzinga Newsdesk - Mar 5, 2024, 10:11AM
Mizuho Maintains Buy on BridgeBio Pharma, Lowers Price Target to $53
Benzinga Newsdesk - Mar 5, 2024, 8:09AM

Monday, March 04, 2024

BridgeBio Pharma Announces Proposed Public Offering Of $250M Of Common Stock
Benzinga Newsdesk - Mar 4, 2024, 4:19PM
What's Going On With BridgeBio Pharma Stock On Monday?
Vandana Singh - Mar 4, 2024, 12:31PM
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $47 Price Target
Benzinga Newsdesk - Mar 4, 2024, 7:47AM
BridgeBio Pharma And Bayer Announce European Licensing Agreement For Acoramidis In ATTR-CM, BridgeBio To Receive $310M Plus Royalties
Benzinga Newsdesk - Mar 4, 2024, 2:34AM

Thursday, February 22, 2024

Recap: BridgeBio Pharma Q4 Earnings
Benzinga Insights - Feb 22, 2024, 8:20AM
BridgeBio Pharma Q4 EPS $(0.96) Misses $(0.91) Estimate, Sales $1.75M Down From $1.87M YoY
Benzinga Newsdesk - Feb 22, 2024, 7:50AM

Thursday, February 15, 2024

Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
Avi Kapoor - Feb 15, 2024, 10:23AM

Wednesday, February 07, 2024

BridgeBio, Kyowa Kirin Ink Partnership With An Upfront Payment Of $100M For Exclusive License On Infigratinib In Skeletal Dysplasias In Japan
Benzinga Newsdesk - Feb 7, 2024, 7:37AM

Monday, February 05, 2024

The FDA Has Bridgebio Pharma's New Drug Application For Acoramidis For Transthyretin Amyloid Cardiomyopathy, With An Action Date Of November 29
Benzinga Newsdesk - Feb 5, 2024, 7:34AM

Friday, February 02, 2024

AstraZeneca's Results From Japan Phase 3 Trial Of Acoramidis For Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Is Consistent With BridgeBio Pharma's ATTRibute-CM Phase 3 Trial, Including Survival, Cardiac-Related Hospitalizations
Benzinga Newsdesk - Feb 2, 2024, 4:51AM

Wednesday, January 31, 2024

BMO Capital Initiates Coverage On BridgeBio Pharma with Market Perform Rating, Announces Price Target of $37
Benzinga Newsdesk - Jan 31, 2024, 6:02AM

Tuesday, January 30, 2024

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
Benzinga Newsdesk - Jan 30, 2024, 7:07AM

Monday, January 29, 2024

HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Raises Price Target to $47
Benzinga Newsdesk - Jan 29, 2024, 6:37AM

Monday, January 22, 2024

Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $50 Price Target
Benzinga Newsdesk - Jan 22, 2024, 8:46AM

Thursday, January 18, 2024

BridgeBio Pharma shares are trading higher after the company announced strategic financing from Blue Owl Capital and Canada Pension Plan Investment Board.
Benzinga Newsdesk - Jan 18, 2024, 11:09AM
BridgeBio Pharma Announced Strategic Financing From Blue Owl Capital And Canada Pension Plan Investment Board Bringing In Capital Of Up To $1.25B
Benzinga Newsdesk - Jan 18, 2024, 7:01AM

Wednesday, January 10, 2024

BridgeBio Reports Publication Of Results From Phase 3 ATTRibute-CM Study Of Acoramidis For Patients With Transthyretin Amyloid Cardiomyopathy In The New England Journal of Medicine
Benzinga Newsdesk - Jan 10, 2024, 5:17PM

Wednesday, January 03, 2024

FDA Has Cleared BridgeBio Pharma's Investigational New Drug Application For BBO-8520, Direct Inhibitor Of Krasg12C (ON); Enrollment Is Expected To Start In 1H Of 2024 Of KRASG12C Mutant Non-Small Cell Lung Cancer Patients In ONKORAS-101 Trial
Benzinga Newsdesk - Jan 3, 2024, 7:34AM

Wednesday, December 13, 2023

Bridgebio Pharma Has Dosed The First Child In PROPEL 3 Phase 3 Trial Of Infigratinib In Children With Achondroplasia; Bridgebio Expects To Begin Development Of Infigratinib In Hypochondroplasia, And Start Observational Lead-in Study In 1H 2024
Benzinga Newsdesk - Dec 13, 2023, 7:32AM

Thursday, December 07, 2023

A Closer Look at BridgeBio Pharma's Options Market Dynamics
Benzinga Insights - Dec 7, 2023, 11:32AM

Tuesday, December 05, 2023

BridgeBio Pharma Submits NDA For Acoramidis To FDA For Treatment Of Transthyretin Amyloid Cardiomyopathy
Benzinga Newsdesk - Dec 5, 2023, 8:21AM

Sunday, November 12, 2023

BridgeBio Pharma Presented Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopath
Charles Gross - Nov 12, 2023, 10:43AM

Friday, November 10, 2023

10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights - Nov 10, 2023, 12:35PM

Thursday, November 09, 2023

BridgeBio Pharma To Present Additional Data From The Phase 3 ATTRibute-CM Study In Patients With Transthyretin Amyloid Cardiomyopathy At The American Heart Association Scientific Sessions 2023
Benzinga Newsdesk - Nov 9, 2023, 8:28AM

Wednesday, November 08, 2023

Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?
Vandana Singh - Nov 8, 2023, 1:20PM

Tuesday, November 07, 2023

Rare Disease Player BridgeBio Pharma's Upside Potential Is Significant According to Citi Analyst - Here's Why
Vandana Singh - Nov 7, 2023, 4:27PM
Citigroup Initiates Coverage On BridgeBio Pharma with Buy Rating, Announces Price Target of $42
Benzinga Newsdesk - Nov 7, 2023, 10:30AM

Thursday, November 02, 2023

BridgeBio Pharma Q3 EPS $(1.08) Misses $(0.81) Estimate, Sales $4.09M Miss $4.26M Estimate
Benzinga Newsdesk - Nov 2, 2023, 7:56AM

Tuesday, October 24, 2023

Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2023
Benzinga Insights - Oct 24, 2023, 11:00AM
The Latest Analyst Ratings for BridgeBio Pharma
Benzinga Insights - Oct 24, 2023, 8:01AM
Cantor Fitzgerald Initiates Coverage On BridgeBio Pharma with Overweight Rating, Announces Price Target of $50
Benzinga Newsdesk - Oct 24, 2023, 5:01AM

Tuesday, October 10, 2023

Bridgebio Pharma Announced That The Proof-of-concept Phase 2B Data Evaluating The Effects Of Encaleret On Mineral Homeostasis In ADH1 Were Published In The New England Journal Of Medicine In Partnership With The National Institutes Of Health
Benzinga Newsdesk - Oct 10, 2023, 7:35AM

Monday, October 09, 2023

BridgeBio Pharma Shares Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-Dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Benzinga Newsdesk - Oct 9, 2023, 7:32AM

Tuesday, October 03, 2023

Bridgebio Pharma And National Resilience Collaborate To Manufacture, Advance BBP-812, An Investigational Adeno-associated Virus (AAV) 9 Gene Therapy For Canavan Disease, And BBP-631, An Investigational AAV 5 Gene Therapy For Congenital Adrenal Hyperplasia
Benzinga Newsdesk - Oct 3, 2023, 7:36AM

Thursday, September 28, 2023

Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
Vandana Singh - Sep 28, 2023, 2:29PM
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights - Sep 28, 2023, 1:35PM

Monday, September 25, 2023

Bridgebio Pharma Announced A Private Placement Of Around 9.2M Shares At The Closing Price Of $27.27 Per Share With Gross Proceeds Of Approximately $250M
Benzinga Newsdesk - Sep 25, 2023, 7:33AM

Thursday, September 07, 2023

BridgeBio Pharma Unusual Options Activity
Benzinga Insights - Sep 7, 2023, 2:32PM

Wednesday, September 06, 2023

The FDA, European Medicines Agency Indicated That A Single, One-year, 2:1 Randomized, Placebo-controlled Trial Would Be Acceptable As A Registrational Study For Bridgebio Pharma's Infigratinib Approval For Children With Achondroplasia
Benzinga Newsdesk - Sep 6, 2023, 7:36AM

Monday, August 28, 2023

What's Going On With BridgeBio Pharma Stock Today?
Vandana Singh - Aug 28, 2023, 2:05PM
Mizuho Reiterates Buy on BridgeBio Pharma, Maintains $60 Price Target
Benzinga Newsdesk - Aug 28, 2023, 9:58AM
Looking At BridgeBio Pharma's Recent Unusual Options Activity
Benzinga Insights - Aug 28, 2023, 9:46AM
BridgeBio shares are trading higher after the company presented detailed results from Phase 3 ATTRibute-CM study of acoramidis in transthyretin amyloid cardiomyopathy at European Society of Cardiology Congress 2023.
Benzinga Newsdesk - Aug 28, 2023, 6:47AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved